Stearoyl-L-carnitine-d3 (chloride)
(Synonyms: CAR 18:0-d3, C18:0 Carnitine-d3, L-Carnitine octdecanoyl ester-d3, L-Carnitine stearoyl ester-d3, L-Octadecanoylcarnitine-d3, Octadecanoyl-L-carnitine-d3, L-Stearoylcarnitine-d3, R-Stearoyl carnitine-d3) 目录号 : GC48107
An internal standard for the quantification of stearoyl-L-carnitine
Cas No.:2245711-27-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Stearoyl-L-carnitine-d3 (chloride) is intended for use as an internal standard for the quantification of stearoyl-L-carnitine by GC- or LC-MS. Stearoyl-L-carnitine is a naturally occurring long-chain acylcarnitine.1 It inhibits sodium-dependent [3H]carnitine uptake in human proximal convoluted tubular (HPCT) cells by 52% when used at a concentration of 500 μM.2 It also inhibits lecithin:cholesterol acyltransferase activity in rat, but not human, plasma when used at a concentration of 500 µM.3 Plasma levels of stearoyl-L-carnitine are decreased in patients with chronic fatigue syndrome and increased in patients with end-stage renal disease.4,1
1.Reuter, S.E., Evans, A.M., Faull, R.J., et al.Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal diseaseAnn. Clin. Biochem.42(Pt 5)387-393(2005) 2.Huang, W., Shaikh, S.N., Ganapathy, M.E., et al.Carnitine transport and its inhibition by sulfonylureas in human kidney proximal tubular epithelial cellsBiochem. Pharmacol.58(8)1361-1370(1999) 3.Bell, F.P.Carnitine esters: Novel inhibitors of plasma lecithin: Cholesterol acyltransferase in experimental animals but not in man (Homo sapiens)Int. J. Biochem.15(2)133-136(1983) 4.Reuter, S.E., and Evans, A.M.Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activityJ. Intern. Med.270(1)76-84(2011)
| Cas No. | 2245711-27-5 | SDF | |
| 别名 | CAR 18:0-d3, C18:0 Carnitine-d3, L-Carnitine octdecanoyl ester-d3, L-Carnitine stearoyl ester-d3, L-Octadecanoylcarnitine-d3, Octadecanoyl-L-carnitine-d3, L-Stearoylcarnitine-d3, R-Stearoyl carnitine-d3 | ||
| Canonical SMILES | OC(C[C@H](C[N+](C([2H])([2H])[2H])(C)C)OC(CCCCCCCCCCCCCCCCC)=O)=O.[Cl-] | ||
| 分子式 | C25H47D3NO4.Cl | 分子量 | 467.1 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 14 mg/ml,Ethanol: 20 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1409 mL | 10.7043 mL | 21.4087 mL |
| 5 mM | 0.4282 mL | 2.1409 mL | 4.2817 mL |
| 10 mM | 0.2141 mL | 1.0704 mL | 2.1409 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet